Introduction
Substantial advances have been made in understanding the molecular biology that drives carcinogenesis and cancerassociated proliferative and antiapoptotic signaling pathways. A wide variety of potentially "druggable" molecular targets for cancer therapy have emerged from these studies. Although a large number of molecular targeted agents have subsequently been tested, most of which showed substantial activity in available preclinical models, relatively few have been successful 8 Chief among the many obstacles to development of effective anticancer regimens is the complexity of tumor signal transduction networks, with parallel pathways, crosstalk, compensatory feedback mechanisms, and extensive interactions between tumor cells and their microenvironment, which cannot be replicated in conventional preclinical models taken in isolation. Adding to these complexities are the interand intrapatient tumor heterogeneity characteristic of human cancers and the innate adaptability of tumor mutator phenotypes, resulting in rapid development of resistance mechanisms. Taken together, these challenges necessitate new ways of thinking regarding the role of preclinical models in cancer drug development.
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Addressing an Unmet Need for Improving Drug Development Strategies in NSCLC This need for improved preclinical platforms is particularly relevant to NSCLC, a worldwide health care epidemic for which most systemic therapies offer only modest benefit. For most patients with advanced NSCLC, the therapeutic decision-making process has remained largely empiric, based on factors such as historical treatment precedent, individual patient characteristics, and physician or patient preferences. Although the feasibility of selecting treatment for individual cancer patients based on tumor molecular profiles (personalized therapy or precision medicine) is already being explored in NSCLC, these efforts have been hampered considerably by tumor heterogeneity and the complexity of the underlying biologic pathways, and suboptimal preclinical models in which individualized therapeutic strategies can be tested. 1, 3, 7 Further, improved strategies to identify and overcome mechanisms of de novo and acquired resistance to treatment are essential to increasing survival and cure rates. [10] [11] [12] [13] Already, transgenic or knock-in preclinical systems such as genetically engineered mouse models (GEMMs) have proven to be invaluable tools for understanding carcinogenesis, tumor biology, and target validation for therapeutics in ways not addressable with other modeling approaches.
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GEMMs represent nonhuman cancers lacking the range of tumor heterogeneity and complexity of biologic pathways inherent to human cancers and present within patient-derived xenografts (PDXs). Although preliminary studies have already demonstrated that chemotherapeutic agents and biologic therapies can be administered and assessed in a systematic fashion using in vivo xenotransplantation PDX models, systematic development, clinical-genomic annotation, and drug testing paradigms have yet to be comprehensively evaluated. The Jackson Laboratory NSG Model for PDX The JAX NSG model is of particular interest for PDX development. Lacking functional B and T cells and natural killer cell activity, the NSG mouse is the most immunodeficient yet physiologically durable murine model available for consistent xenoengraftment of human primary tumors. 24 These attributes of the NSG mouse model facilitate engraftment of a wide variety of human cancers, with excellent correlation of histomorphological and molecular features between PDX tumors and the original human cancers as described herein. Ongoing studies at JAX are focusing on optimization of the engraftment algorithm, such as use of small biopsy samples acquired using core needle biopsy (minimum of 1 mm 3 of tissue) and "transportability" of viable patient tumor specimens from other institutions. For example, engraftment rates appear similar between specimens acquired locally in Sacramento versus those express-shipped overnight from sites across the country, overall exceeding 40% for NSCLC specimens from advanced-stage disease.
Integrated Clinical and Genomic Annotation of Patient Tumor and Corresponding PDX
The algorithm for PDX creation and analysis after patient tumor biopsy is shown in Figure 1 . In a synchronized evaluation process, patient tumors (PTs) and subsequent PDXs undergo histomorphologic assessment by a single reference pathologist, biomarker testing at the Clinical Laboratory Improvement Amendments (CLIA) laboratory at Response Genetics, Inc, and genomic analysis using multiple platforms including gene expression arrays and next-generation sequencing. PDXs of interest, based on molecular subtyping (eg, EGFR-mutated, Kirsten rat sarcoma or KRAS-mutated, squamous, etc) are then grouped into panels for subsequent drug testing. Figure 2 demonstrates how a panel (eg, EGFR-mutated) is subgrouped according to mutation type, resistance mechanism (if known), and clinical annotation (sensitive to EGFR tyrosine kinase inhibitor, de novo resistance, or acquired resistance). Patient clinical annotation is tracked (case example as shown in Figure 3 ) to account for all pertinent patient demographic characteristics, including smoking status, treatment records, and timing of PDX 
Drug Testing Paradigm
A variety of projects are ongoing to test PDX panels of interest for new drug treatment strategies, and to determine mechanisms of resistance and how to overcome them. A combination of tumor growth inhibition studies and real-time tumor pharmacodynamics are incorporated into each drug testing project (Figure 4 ). An advantage of this testing paradigm in these is that degrees of responsiveness can be quantitatively measured to provide a more nuanced assessment of the pharmacologic effect of any drug or drug combination. Moreover, the availability of an annotated panel of xenografts for a particular genetic mutation or histology should increase the likelihood of discovery of new genomic signatures of drug sensitivity and resistance. The use of these models in coclinical trials is of particular interest.
An ongoing pilot study to investigate mechanisms of acquired drug resistance in EGFR-mutated lung cancer, for example, is using a panel of EGFR-mutated PDXs to investigate a drug regimen of afatinib with or without cetuximab, using erlotinib and vehicle as controls. Results in 2 PDX models, one in which the host patient proved to subsequently be responsive to the afatinibcetuximab combination and the other patient was unresponsive, mimicked the clinical outcomes, as shown in Figure 5 . Associated tumor pharmacodynamics ( Figure 6 ) illustrates abrogation of multiple signal transduction pathways globally mediated by maximal EGFR inhibition in the sensitive model (LG0703), in contrast to incomplete EGFR inhibition coupled with compensatory upregulation of survival pathways in the resistant model (LG1049). These data suggest that PDX models can recapitulate drug treatment outcomes in patients from whom the PDXs were derived, and that investigations can be designed to increase understanding of underlying biologic pathways and to devise strategies to improve effectiveness of therapy. This hypothesis will be tested in a future Southwestern Oncology Group phase II/III clinical trial (S1403) that will compare afatinib with or without cetuximab in the first-line therapy of patients with EGFR-mutated lung cancer, in which selected patients will undergo repeat tumor biopsy at the time of progressive disease, for genomic assessment and for PDX creation and drug testing.
Summary
The integrated preclinical-clinical modeling strategy described herein, that uses a large annotated NSG mouse resource of PDX 
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Clinical Lung Cancer May 2015 -169 models, provides a novel research tool for drug development and for understanding the genomic complexity of lung cancer. Prospective development of PDXs from mutation-specific cohorts of patients treated in a homogeneous fashion, such as the planned PDX project associated with the S1403 clinical trial, should provide a unique resource for future study. It is anticipated that availability of such an annotated resource will assist in optimization of therapeutic strategies and lead to improved patient outcomes.
